Stockreport

Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284

Intra-Cellular Therapies Inc.  (ITCI) 
Last intra-cellular therapies inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intracellulartherapies.com/investor-relations
PDF ITI-1284 is a deuterated form of lumateperone delivered sublingually as an orally disintegrating tablet (ODT-SL). ITI-1284 ODT-SL may offer pharmacologic benefits and ea [Read more]